Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors

US8546394B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Jun Li · Foster City, US
• James J. Li · Pennington, US
• Stephen P. O'Connor · Newtown, US
• Haixia Wang · San Diego, US
• Lawrence J. Kennedy · Titusville, US
• Jeffrey A. Robl · Newtown, US
• Lawrence G. Hamann · North Grafton, US

Key dates

• Filing date: Apr 16, 2008
• Grant date: Oct 1, 2013
• Expiry date: Jul 11, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel compounds are provided which are 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors. 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 1 1-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: W-L-Z or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L are defined herein and Z is selected from the following bicyclic heteroaryl groups: (a), (b), (c), (d).